University of California San Diego Health

AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare

Gene expression patterns associated with pandemic viral infections provide a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics

Newswise — Researchers at University of California San Diego School of Medicine used an artificial intelligence (AI) algorithm to sift through terabytes of gene expression data — which genes are “on” or “off” during infection — to look for shared patterns in patients with past pandemic viral infections, including SARS, MERS and swine flu.

Two telltale signatures emerged from the study, published June 11, 2021 in eBiomedicine. One, a set of 166 genes, reveals how the human immune system responds to viral infections. A second set of 20 signature genes predicts the severity of a patient’s disease. For example, the need to hospitalize or use a mechanical ventilator. The algorithm’s utility was validated using lung tissues collected at autopsies from deceased patients with COVID-19 and animal models of the infection.

“These viral pandemic-associated signatures tell us how a person’s immune system responds to a viral infection and how severe it might get, and that gives us a map for this and future pandemics,” said Pradipta Ghosh, MD, professor of cellular and molecular medicine at UC San Diego School of Medicine and Moores Cancer Center.

Ghosh co-led the study with Debashis Sahoo, PhD, assistant professor of pediatrics at UC San Diego School of Medicine and of computer science and engineering at Jacobs School of Engineering, and Soumita Das, PhD, associate professor of pathology at UC San Diego School of Medicine.

During a viral infection, the immune system releases small proteins called cytokines into the blood. These proteins guide immune cells to the site of infection to help get rid of the infection. Sometimes, though, the body releases too many cytokines, creating a runaway immune system that attacks its own healthy tissue. This mishap, known as a cytokine storm, is believed to be one of the reasons some virally infected patients, including some with the common flu, succumb to the infection while others do not.

But the nature, extent and source of fatal cytokine storms, who is at greatest risk and how it might best be treated have long been unclear.

“When the COVID-19 pandemic began, I wanted to use my computer science background to find something that all viral pandemics have in common — some universal truth we could use as a guide as we try to make sense of a novel virus,” Sahoo said. “This coronavirus may be new to us, but there are only so many ways our bodies can respond to an infection.”

The data used to test and train the algorithm came from publicly available sources of patient gene expression data — all the RNA transcribed from patients’ genes and detected in tissue or blood samples. Each time a new set of data from patients with COVID-19 became available, the team tested it in their model. They saw the same signature gene expression patterns every time.

“In other words, this was what we call a prospective study, in which participants were enrolled into the study as they developed the disease and we used the gene signatures we found to navigate the uncharted territory of a completely new disease,” Sahoo said.

By examining the source and function of those genes in the first signature gene set, the study also revealed the source of cytokine storms: the cells lining lung airways and white blood cells known as macrophages and T cells. In addition, the results illuminated the consequences of the storm: damage to those same lung airway cells and natural killer cells, a specialized immune cell that kills virus-infected cells.

“We could see and show the world that the alveolar cells in our lungs that are normally designed to allow gas exchange and oxygenation of our blood, are one of the major sources of the cytokine storm, and hence, serve as the eye of the cytokine storm,” Das said. “Next, our HUMANOID Center team is modeling human lungs in the context of COVID-19 infection in order to examine both acute and post-COVID-19 effects.”

The researchers think the information might also help guide treatment approaches for patients experiencing a cytokine storm by providing cellular targets and benchmarks to measure improvement.

To test their theory, the team pre-treated rodents with either a precursor version of Molnupiravir, a drug currently being tested in clinical trials for the treatment of COVID-19 patients, or SARS-CoV-2-neutralizing antibodies. After exposure to SARS-CoV-2, the lung cells of control-treated rodents showed the pandemic-associated 166- and 20-gene expression signatures. The treated rodents did not, suggesting that the treatments were effective in blunting cytokine storm.

“It is not a matter of if, but when the next pandemic will emerge,” said Ghosh, who is also director of the Institute for Network Medicine and executive director of the HUMANOID Center of Research Excellence at UC San Diego School of Medicine. “We are building tools that are relevant not just for today’s pandemic, but for the next one around the corner.”

Co-authors of the study include: Gajanan D. Katkar, Soni Khandelwal, Mahdi Behroozikhah, Amanraj Claire, Vanessa Castillo, Courtney Tindle, MacKenzie Fuller, Sahar Taheri, Stephen A. Rawlings, Victor Pretorius, David M. Smith, Jason Duran, UC San Diego; Thomas F. Rogers, Scripps Research and UC San Diego; Nathan Beutler, Dennis R. Burton, Scripps Research; Sydney I. Ramirez, La Jolla Institute for Immunology; Laura E. Crotty Alexander, VA San Diego Healthcare System and UC San Diego; Shane Crotty, Jennifer M. Dan, La Jolla Institute for Immunology and UC San Diego.

Funding for this research came, in part, from the National Institutes for Health (grants R00-CA151673, R01-GM138385, R01-AI141630, CA100768, CA160911, R01DK107585, R01-AI155696, R00RG2628, R00RG2642 and U19-AI142742), UC San Diego Sanford Stem Cell Clinical Center, La Jolla Institute for Immunology Institutional Funds, and VA San Diego Healthcare System.

###

SEE ORIGINAL STUDY



Filters close

Showing results

110 of 5872
Released: 24-Jun-2021 4:55 PM EDT
Virus that causes COVID-19 can find alternate route to infect cells
Washington University in St. Louis

The virus that causes COVID-19 normally gets inside cells by attaching to a protein called ACE2. Researchers at Washington University School of Medicine in St. Louis have found that a single mutation confers the ability to enter cells through another route, which may threaten the effectiveness of COVID-19 vaccines and therapeutics designed to block the standard route of entry.

Newswise: Is it a Virus or Bacteria? New Tech Rapidly Tests for COVID-19 and More
Released: 24-Jun-2021 3:05 PM EDT
Is it a Virus or Bacteria? New Tech Rapidly Tests for COVID-19 and More
Homeland Security's Science And Technology Directorate

S&T is preparing for future outbreaks/pandemics by investing in a new tech that can quickly discriminate between bacterial and viral infections so that the U.S. can triage patients and plan a response without delay.

Released: 24-Jun-2021 12:30 PM EDT
A tecnologia de IA e ECG pode descartar rapidamente a infecção por COVID-19, concluiu o estudo da Mayo Clinic
Mayo Clinic

A inteligência artificial (IA) pode oferecer uma maneira de determinar com precisão se uma pessoa não está infectada com a COVID-19. Um estudo retrospectivo internacional descobriu que a infecção pelo SARS-CoV-2, o vírus que causa a COVID-19, cria mudanças elétricas sutis no coração. Um eletrocardiograma (ECG) habilitado com IA pode detectar essas alterações e, potencialmente, ser usado como um teste de triagem rápido e confiável para descartar a infecção por COVID-19.

Released: 24-Jun-2021 12:10 PM EDT
妙佑医疗国际(Mayo Clinic)的研究发现,AI赋能的心电图技术有可能迅速排除COVID-19感染
Mayo Clinic

AI (人工智能)有可能提供准确判断一个人未感染COVID-19(2019冠状病毒病)的方法。一项国际回顾性研究发现,如果感染了导致COVID-19的SARS-CoV-2病毒,患者的心脏会产生微妙的电学变化。AI赋能的心电图(EKG)可以检测到这些变化,并有望被用于进行快速、可靠的COVID-19筛查检测,以排除COVID-19感染。

Newswise: 200421_Felgner_3205_sz-2-768x496.jpg
Released: 24-Jun-2021 11:50 AM EDT
UCI Professor Wins Spain’s Prestigious Princess of Asturias Award for Scientific Research
University of California, Irvine

Irvine, Calif., June 24, 2021 — Philip Felgner, Ph.D., professor in residence of physiology & biophysics at the University of California, Irvine, is one of seven scholars worldwide to win Spain’s prestigious Princess of Asturias Award for Technical and Scientific Research in recognition of their contributions to designing COVID-19 vaccines.

Released: 24-Jun-2021 11:00 AM EDT
New protein engineering method could accelerate the discovery of COVID-19 therapeutics
University of Michigan

Discovering and engineering nanobodies with properties suitable for treating human diseases ranging from cancer to COVID-19 is a time-consuming, laborious process.

Newswise: Decoding humans’ survival from coronaviruses
Released: 24-Jun-2021 11:00 AM EDT
Decoding humans’ survival from coronaviruses
University of Adelaide

An international team of researchers co-led by the University of Adelaide and the University of Arizona has analysed the genomes of more than 2,500 modern humans from 26 worldwide populations, to better understand how humans have adapted to historical coronavirus outbreaks.

access_time Embargo lifts in 2 days
Embargo will expire: 29-Jun-2021 4:00 PM EDT Released to reporters: 24-Jun-2021 10:35 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 29-Jun-2021 4:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: COVIDLockdownSimulations.jpg
Released: 24-Jun-2021 10:00 AM EDT
Pandemic Air Quality Affected By Weather, Not Just Lockdowns
Washington University in St. Louis

Using a diverse set of tools, the lab of Randall Martin shows how the pandemic did – or didn’t – affect levels of particulate matter during COVID lockdowns.

Released: 24-Jun-2021 6:05 AM EDT
Longest known SARS-CoV-2 infection of nearly 300 days successfully treated with new therapy
University of Bristol

An immunocompromised individual with the longest known PCR confirmed case of SARS-CoV-2 infection, lasting more than 290 days, has been successfully treated with two investigational monoclonal antibodies (laboratory engineered antibodies). Clinicians and researchers from the University of Bristol and North Bristol NHS Trust (NBT) worked closely to assess and treat the infection and want to highlight the urgent need for improved access to treatments for such people with persistent SARS-CoV-2 infection.


Showing results

110 of 5872

close
1.80934